Arch Biopartners Inc ACHFF

Primary Symbol: V.ARCH

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Naked Shorting Continues

<< Previous

Bullboard Posts

Next >>

Post by Arbourmarkon Jan 04, 2022 11:18am

177 Views

Post# 34281712

Naked Shorting Continues

We get news release today x as nd share price drops 5%. The same daily pattern continues with the same houses using dark pool trades knock share price lower on low volume.

CIBC and Anonymous are some two involved on this daily trading pattern to knock share price lower. Naked shorting should be investigated but unfortunately in Canada our watch dogs like IRROC and OSC seem to turn a blind eye.

I unfortunately feel this trading pattern will continue until the detailed third party analysis of phase 2 results are released.

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (May 31, 2024)